[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 397,380
  • Shares Outstanding, K 58,139
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,040 K
  • EBIT $ -92 M
  • EBITDA $ -106 M
  • 60-Month Beta 0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.88

Options Overview Details

View History
  • Implied Volatility 335.92% (+0.33%)
  • Historical Volatility 359.25%
  • IV Percentile 91%
  • IV Rank 69.42%
  • IV High 456.20% on 12/02/25
  • IV Low 62.85% on 01/22/26
  • Expected Move (DTE 28) 3.82 (62.46%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 34,129
  • Volume Avg (30-Day) 16,936
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 262,440
  • Open Int (30-Day) 195,226
  • Expected Range 2.29 to 9.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.57
  • Number of Estimates 5
  • High Estimate $-0.40
  • Low Estimate $-0.73
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) -5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.96 +106.93%
on 07/30/26
20.54 -70.18%
on 07/23/26
-13.66 (-69.05%)
since 07/21/26
3-Month
2.96 +106.93%
on 07/30/26
30.93 -80.20%
on 06/25/26
-23.45 (-79.29%)
since 05/21/26
52-Week
2.96 +106.93%
on 07/30/26
40.37 -84.83%
on 12/03/25
-0.89 (-12.68%)
since 08/21/25

Most Recent Stories

More News
INVESTOR DEADLINE: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit Before September 28, 2026 Deadline

SAN DIEGO , Aug. 21, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP  announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities...

CAPR : 6.18 (-9.65%)
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy CAPR securities between December 17, 2025 and July 26, 2026?

CAPR : 6.18 (-9.65%)
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

LOS ANGELES , Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR...

CAPR : 6.18 (-9.65%)
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES , Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP  ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor...

CAPR : 6.18 (-9.65%)
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm to Learn About Their Legal Rights

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 61.75 (-0.18%)
CAPR : 6.18 (-9.65%)
CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact SueWallSt

From Optimism to Disillusionment: Capricor Therapeutics investors watched sentiment collapse from confidence in an August 22, 2026 approval date to a 78.7% share decline after FDA briefing documents ...

CAPR : 6.18 (-9.65%)
Kaplan Fox Alerts Investors to an Upcoming Deadline of September 28, 2026 in the Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Class Action

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 61.75 (-0.18%)
CAPR : 6.18 (-9.65%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

NEW YORK , Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such...

CAPR : 6.18 (-9.65%)
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

SAN FRANCISCO , Aug. 20, 2026 /PRNewswire/ -- National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR) . Following Capricor's...

CAPR : 6.18 (-9.65%)
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 61.75 (-0.18%)
CAPR : 6.18 (-9.65%)

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 8.48
2nd Resistance Point 8.15
1st Resistance Point 7.49
Last Price 6.18
1st Support Level 6.50
2nd Support Level 6.17
3rd Support Level 5.51

See More

52-Week High 40.37
Fibonacci 61.8% 26.08
Fibonacci 50% 21.66
Fibonacci 38.2% 17.25
Last Price 6.18
52-Week Low 2.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.